ZFIN Fish: AB + MO3-zic2a

ZFIN ID: ZDB-FISH-150901-2423

ZFIN ID: ZDB-FISH-150901-2423

Fish name:	AB + MO3-zic2a
Genotype:	AB
Targeting Reagent:	MO3-zic2a

HUMAN DISEASE MODELED by AB + MO3-zic2a
No data available

GENE EXPRESSION
Gene expression in AB + MO3-zic2a

RNA expression

Expressed Gene	Structure	Conditions	Figures
aldh1a3	optic cup	standard conditions	Fig. 6 from Sanek et al., 2009
arxa	ventral thalamus	chemical treatment: ethanol	Fig. 6 from Sanek et al., 2008
	ventral thalamus	standard conditions	Fig. 4 from Sanek et al., 2009 Fig. 1 , Fig. 4 from Sanek et al., 2008
dbx1a	thalamus	standard conditions	Fig. 2 from Sanek et al., 2008
dlx2a	telencephalon ventral thalamus	standard conditions	Fig. 4 from Sanek et al., 2009 Fig. 2 , Fig. 4 , Fig. 5 , Fig. S4 from Sanek et al., 2008
emx1	hypothalamus telencephalon	standard conditions	Fig. 2 from Sanek et al., 2008
eomesa	preoptic area ventral thalamus	standard conditions	Fig. S3 from Sanek et al., 2008
fezf2	ventral thalamus	standard conditions	Fig. S1 from Sanek et al., 2008
fgf8a	optic cup optic stalk	standard conditions	Fig. 5 from Sanek et al., 2009
foxg1a	telencephalon	standard conditions	Fig. 2 , Fig. S3 , Fig. S4 from Sanek et al., 2008
gli1	forebrain	standard conditions	Fig. 7 from Sanek et al., 2008
gli2a	forebrain	standard conditions	Fig. 7 from Sanek et al., 2008
gli3	forebrain	standard conditions	Fig. 7 from Sanek et al., 2008
irx1b	diencephalon thalamus	standard conditions	Fig. 7 , Fig. S1 from Sanek et al., 2008
isl1a	preoptic area telencephalon (not) ventral thalamus	standard conditions	Fig. 3 from Sanek et al., 2008
lef1	diencephalon	standard conditions	Fig. S3 from Sanek et al., 2008
lhx1a	diencephalon	standard conditions	Fig. S3 from Sanek et al., 2008
nkx2.1	hypothalamus	standard conditions	Fig. 2 from Sanek et al., 2008
nkx2.2a	forebrain	standard conditions	Fig. 7 from Sanek et al., 2008
nkx2.4b	hypothalamus telencephalon	standard conditions	Fig. S3 from Sanek et al., 2008
otpb	preoptic area	standard conditions	Fig. 3 from Sanek et al., 2008
oxt	(not) preoptic area	standard conditions	Fig. 3 from Sanek et al., 2008
pax2a	optic cup optic stalk	standard conditions	Fig. 5 , Fig. 6 , Fig. 9 from Sanek et al., 2009
pax6a	telencephalon ventral thalamus	standard conditions	Fig. 2 from Sanek et al., 2008
ptch2	forebrain	standard conditions	Fig. 7 from Sanek et al., 2008
rx3	hypothalamus optic vesicle preoptic area presumptive diencephalon	standard conditions	Fig. 5 from Sanek et al., 2009 Fig. S1 , Fig. S3 from Sanek et al., 2008
shha	floor plate thalamus zona limitans intrathalamica	standard conditions	Fig. 2 , Fig. 7 , Fig. S4 from Sanek et al., 2008
sim1a	preoptic area	standard conditions	Fig. 3 from Sanek et al., 2008
six3b	diencephalon forebrain optic primordium telencephalon	standard conditions	Fig. 2 , Fig. 3 from Sanek et al., 2009 Fig. S1 from Sanek et al., 2008
vax1	optic stalk	standard conditions	Fig. 5 from Sanek et al., 2009

Protein expression

Antibody	Antigen Genes	Structure	Conditions	Figures
Ab1-casp3		diencephalon	standard conditions	text only from Sanek et al., 2008
Ab1-BrdU		ventral thalamus	chemical treatment: 5-bromo-2'-deoxyuridine	Fig. 4 from Sanek et al., 2008

Reporter gene expression No data available

PHENOTYPE
Phenotype in AB + MO3-zic2a

Phenotype	Conditions	Figures
apoptotic process rate, normal	standard conditions	text only from Sanek et al., 2008
cell proliferation in forebrain disrupted, abnormal	chemical treatment: 5-bromo-2'-deoxyuridine	Fig. 4 from Sanek et al., 2008
cell proliferation in forebrain occurrence, normal	chemical treatment: 5-bromo-2'-deoxyuridine	Fig. 4 from Sanek et al., 2008
diencephalon development disrupted, abnormal	standard conditions	Fig. 1 , Fig. 2 , Fig. 5 from Sanek et al., 2008
diencephalon development disrupted, abnormal	chemical treatment: ethanol	Fig. 6 from Sanek et al., 2008
diencephalon development disrupted, abnormal	chemical treatment: ethanol, chemical treatment: Cyclopamine	Fig. 6 from Sanek et al., 2008
negative regulation of DNA-templated transcription disrupted, abnormal	standard conditions	Fig. 2 , Fig. 3 from Sanek et al., 2009
neurogenesis disrupted, abnormal	standard conditions	Fig. 3 from Sanek et al., 2008
optic fissure closure incomplete, abnormal	standard conditions	Fig. 6 from Sanek et al., 2009
regulation of smoothened signaling pathway disrupted, abnormal	standard conditions	Fig. 3 from Sanek et al., 2009
ventral thalamus decreased size, abnormal	standard conditions	Fig. 1 , Fig. 2 , Fig. S3 , Fig. S4 from Sanek et al., 2008
ventral thalamus decreased size, abnormal	chemical treatment: ethanol, chemical treatment: Cyclopamine	Fig. 6 from Sanek et al., 2008
ventral thalamus decreased size, abnormal	chemical treatment: ethanol	Fig. 6 from Sanek et al., 2008

CITATIONS (3)